Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
403
Frequently Asked Questions
What is Market Cap of Intellia Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Intellia Therapeutics Inc market cap is $1.29B.
What is the 52-week high for Intellia Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Intellia Therapeutics Inc 52 week high is $23.76 as of September 08, 2025.
What is the 52-week low for Intellia Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Intellia Therapeutics Inc 52 week low is $5.90 as of September 08, 2025.
What is Intellia Therapeutics Inc stock price today?
Intellia Therapeutics Inc stock price today is $11.84.
What was Intellia Therapeutics Inc stock price yesterday?
Intellia Therapeutics Inc stock price yesterday was $12.06.
What is the PE ratio of Intellia Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Intellia Therapeutics Inc’s P/E ratio is -2.57.
What is the Price-to-Book ratio of Intellia Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Intellia Therapeutics Inc P/B ratio is 1.7760.
What is the 50-day moving average of Intellia Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Intellia Therapeutics Inc 50-day moving average is $11.44.
How many employess does Intellia Therapeutics Inc has?